A Study Comparing SHR-3167 and Insulin Degludec in Type 2 Diabetic Subjects Treated With Basal Insulin With or Without Oral Antidiabetic Drugs

Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Study ID
NCT07018453
Phase
PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • SHR-3167 — DRUG
    SHR-3167 Injection.
  • Insulin Degludec — DRUG
    Insulin Degludec Injection.

Study Details

The purpose of this study is to evaluate the glycemic control and safety of SHR-3167 and Insulin Degludec in type 2 diabetic participants treated with basal insulin with or without oral antidiabetic drugs.

Key Dates

First listed
Jun 12, 2025
Start date
Jul 16, 2025
Status verified
Nov 2025
Primary completion
Feb 28, 2026
Completion
May 31, 2026

Study Design

Enrollment
173 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: SHR-3167 Group A
  • Experimental: SHR-3167 Group B
  • Active Comparator: Insulin Degludec Group

Primary Outcome Measure

Change in glycosylated hemoglobin (HbA1c) from baseline. [ Time Frame: 16 weeks. ]

Find similar trials

Nationwide
Type 2 diabetes trialsEndocrinology trialsMetabolic health trialsWeight loss trials

Related Studies